Journal of Clinical Oncology
Articles in this Issue
Prospective comparison of AR-V7 transcripts from whole blood and circulating tumor cells in castration-resistant prostate cancer patients undergoing treatment with androgen-receptor signaling inhibitors: The PEARL trial.
253 Background: Androgen receptor splice variant 7 (AR-V7) messenger RNA (mRNA) from whole blood (WB) was reported to pred...
An artificial intelligence–digital pathology algorithm to predict outcomes in a cohort of men diagnosed with prostate cancer within a low resource setting.
399 Background: In the era of precision oncology, personalized prognostic biomarkers have demonstrated superior prostate c...
OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
TPS288 Background: An optimal PSA response, defined as ≤0.2 ng/mL is achieved by ~51% of pts with mHSPC at 6–8 months afte...
Contemporary outcomes of nephrectomy with IVC thrombectomy: Analysis from a large multi-institutional database.
469 Background: Nephrectomy with IVC thrombectomy for renal cell carcinoma remains one of the most technically demanding p...
Outcomes of [ <sup>177</sup> Lu]Lu-PSMA-617 ( <sup>177</sup> Lu-PSMA-617) after sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.
88 Background: The VISION (NCT03511664) and PSMAfore (NCT04689828) clinical trials have demonstrated the effectiveness of...
Real-world survival disparities and comorbidity predictors with Lu-177–PSMA-617 and PARP inhibitors in metastatic prostate cancer.
125 Background: Lu-177–PSMA-617 (Pluvicto) and PARP inhibitors represent distinct targeted treatment paradigms in metastat...
Perioperative outcomes from a randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robot-assisted radical prostatectomy (RARP).
369 Background: MRI-guided transurethral ultrasound ablation (TULSA) uses MRI to target, monitor, and control thermal abla...
Treatment patterns, attrition, and survival outcomes in patients with metastatic unclassified renal cell carcinoma.
463 Background: Unclassified or not otherwise specified (NOS) renal cell carcinoma (RCC) is a rare and heterogeneous subty...
Evaluating the relationship between vasculitis and metastasis in kidney-related urogenital cancers: A multicenter real-world propensity-matched cohort study.
561 Background: Vasculitis, a disorder with systemic inflammation and immune dysregulation, can create a pro-tumorigenic m...
The efficacy and safety of <sup>177</sup> Lu-PSMA-617 in Chinese patients with post-taxane metastatic castration-resistant prostate cancer: From a multicenter phase II study.
181 Background: The global phase III VISION trial established the efficacy of 177...
Angelica herbal supplement AGN-Cogni.Q acute dose safety and pharmacokinetics (PK) dose-response in prostate cancer patients.
372 Background: There are currently no FDA approved modalities for intercepting prostate cancer biochemical recurrence aft...
Adiposity and response to ADT ± AR pathway inhibitors (ARPI) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
233 Background: Adiposity has a complex influence on prostate cancer outcomes that may be stage- and/or treatment-dependen...
<i>PARP1</i> and <i>BRCA1/2</i> expression and overall survival in high risk of recurrence localized clear cell-type renal cell carcinoma.
514 Background: Poly(ADP-ribose) polymerase 1 (PARP1) senses single strand DNA damage and catalyzes repair mechanisms. PAR...
Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC).
197 Background: Cytoreductive prostatectomy (CRP) may provide oncologic benefit for specific patients. The goal of this st...
Estimated net benefit of talazoparib (TALA) + enzalutamide (ENZA) for patients (Pts) with mCRPC using a Q-TWiST analysis.
194 Background: In TALAPRO-2, 1L TALA + ENZA showed significantly prolonged OS and rPFS vs placebo (PBO) + ENZA in pts uns...
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer: The RAD VACCINE MIBC clinical trial.
750 Background: Up to 50% of patients with muscle invasive bladder cancer (MIBC) are ineligible for cisplatin-based neoadj...
Correlation without causality between BAP1 loss and the metastasis-associated <i>miR-183/96/182</i> cluster expression in renal cell carcinoma.
531 Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma and is characte...
Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: A subgroup analysis of the phase II POLARIS-03 trial.
817 Background: Toripalimab, a PD-1 inhibitor, is approved in China as second-line therapy for metastatic urothelial carci...
Trends in advanced-stage prostate cancer over the last decade: Analysis from the National Cancer Database (NCDB).
48 Background: The incidence of stage IV prostate cancer in the United States has risen over the past decade, possibly ref...
Enhancing post-HIFU surveillance: Diagnostic performance of 18F-PSMA PET/CT and mpMRI for local prostate cancer recurrence.
313 Background: Focal therapy (FT), including high-intensity focused ultrasound (HIFU), has emerged as a minimally invasiv...
Ethnic disparities and variations in testicular germ cell tumours: A retrospective real-world analysis in a single tertiary cancer centre.
595 Background: Testicular germ cell tumours (TGCTs) are the most common malignancy in young men. Ethnic disparities and v...
CARPET trial: A phase II trial evaluating trastuzumab deruxtecan in metastatic castration-resistant prostate cancer.
TPS303 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge, as standard th...
A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.
161 Background: Progression to mCRPC is driven by numerous mechanisms including emergence of AR LBD mutations that reactiv...
Fixed low-dose nab-paclitaxel with tislelizumab in non-metastatic bladder cancer: A post-hoc analysis of dose expose in TRUCE-01 and TRUCE-02 trials.
768 Background: Although PD-1 immune checkpoint inhibitors (PD-1 ICIs) show efficacy in bladder cancer, exploring effectiv...
A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non-clear cell renal cell carcinoma.
506 Background: Non-clear cell renal cell carcinoma (nccRCC) is a rare and heterogeneous disease with limited treatment ev...